28 research outputs found
Reversible melting and equilibrium phase formation of (Bi,Pb)2Sr2Ca2Cu3O10+d
The decomposition and the reformation of the (Bi,Pb)2Sr2Ca2Cu3O10+d
(?Bi,Pb(2223)?) phase have been investigated in-situ by means of
High-Temperature Neutron Diffraction, both in sintered bulk samples and in
Ag-sheathed monofilamentary tapes. Several decomposition experiments were
performed at various temperatures and under various annealing atmospheres,
under flowing gas as well as in sealed tubes, in order to study the appropriate
conditions for Bi,Pb(2223) formation from the melt. The Bi,Pb(2223) phase was
found to melt incongruently into (Ca,Sr)2CuO3, (Sr,Ca)14Cu24O41 and a
Pb,Bi-rich liquid phase. Phase reformation after melting was successfully
obtained both in bulk samples and Ag-sheathed tapes. The possibility of
crystallising the Bi,Pb(2223) phase from the melt was found to be extremely
sensitive to the temperature and strongly dependent on the Pb losses. The study
of the mass losses due to Pb evaporation was complemented by thermogravimetric
analysis which proved that Pb losses are responsible for moving away from
equilibrium and therefore hinder the reformation of the Bi,Pb(2223) phase from
the melt. Thanks to the full pattern profile refinement, a quantitative phase
analysis was carried out as a function of time and temperature and the role of
the secondary phases was investigated. Lattice distortions and/or transitions
were found to occur at high temperature in Bi,Pb(2223), Bi,Pb(2212),
(Ca,Sr)2CuO3 and (Sr,Ca)14Cu24O41, due to cation diffusion and stoichiometry
changes. The results indicate that it is possible to form the Bi,Pb(2223) phase
from a liquid close to equilibrium conditions, like Bi(2212) and Bi(2201), and
open new unexplored perspectives for high-quality Ag-sheathed Bi,Pb(2223) tape
processing.Comment: 45 pages (including references,figures and captions), 13 figures
Submitted to Supercond. Sci. Techno
Recommended from our members
Vertical structure and physical processes of the Madden-Julian oscillation: exploring key model physics in climate simulations
Aimed at reducing deficiencies in representing the Madden-Julian oscillation (MJO) in general circulation models (GCMs), a global model evaluation project on vertical structure and physical processes of the MJO was coordinated. In this paper, results from the climate simulation component of this project are reported. It is shown that the MJO remains a great challenge in these latest generation GCMs. The systematic eastward propagation of the MJO is only well simulated in about one-fourth of the total participating models. The observed vertical westward tilt with altitude of the MJO is well simulated in good MJO models, but not in the poor ones. Damped Kelvin wave responses to the east of convection in the lower troposphere could be responsible for the missing MJO preconditioning process in these poor MJO models.
Several process-oriented diagnostics were conducted to discriminate key processes for realistic MJO simulations. While large-scale rainfall partition and low-level mean zonal winds over the Indo-Pacific in a model are not found to be closely associated with its MJO skill, two metrics, including the low-level relative humidity difference between high and low rain events and seasonal mean gross moist stability, exhibit statistically significant correlations with the MJO performance. It is further indicated that increased cloud-radiative feedback tends to be associated with reduced amplitude of intraseasonal variability, which is incompatible with the radiative instability theory previously proposed for the MJO. Results in this study confirm that inclusion of air-sea interaction can lead to significant improvement in simulating the MJO
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
BACKGROUND:
Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes.
METHODS:
We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization.
RESULTS:
During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events.
CONCLUSIONS:
Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)